Table 2 Results of cost-effectiveness analysis

From: Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers

  Scenario 1 Scenario 2 Scenario 2 vs. scenario 1
  Testing No testing Increment Testing No testing Increment  
Cost (discounted) AU$5,955 AU$4,076 AU$1,880 AU$8,602 AU$6,067 AU$2,535 AU$665
QALYs (discounted) 15.83 15.73 0.10 22.54 22.37 0.17 0.07
ICER/QALY    AU$18,900    AU$14,900 AU$9,500
Life-years 17.47 17.38 0.09 66.81 66.11 0.70 0.61
Breast cancer events 0.23 0.28 −0.04 0.31 0.41 −0.10 −0.06
Ovarian cancer events 0.04 0.05 −0.01 0.08 0.10 −0.02 −0.01
  1. Scenario 1, testing affected individuals only compared with no testing; scenario 2, testing affected individuals and cascade testing in family members of mutation carriers compared with no testing; scenario 2 vs. scenario 1, testing affected individuals and cascade testing in family members of mutation carriers versus testing affected individuals only. AU$, Australian dollar; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.